Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · Real-Time Price · USD

25.21

-0.40 (-1.56%)

At close: Aug 31, 2026, 4:00 PM EDT

25.21

0.00 (0.00%)

Pre-market: Sep 1, 2026, 4:28 AM EDT

Ultragenyx Pharmaceutical Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	717	673	560	434	363.33	351.41
Revenue Growth	17.51%	20.18%	29.03%	19.45%	3.39%	29.66%
Gross Profit	-149	-186	-215	-259	-370.78	-161.76
Operating Income	-498	-535	-536	-569	-648.92	-381.74
Net Income	-586	-575	-569	-607	-707.42	-454.03
Earnings Per Share	-5.83	-5.83	-6.29	-8.26	-10.12	-6.70
EPS Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Crysvita	187	177	134.71	75.7	42.68	21.42
Dojolvi	101.28	96	88.19	70.63	55.61	39.56
Evkeeza	72.72	59	32.16	3.64	-	-
Mepsevii	37	37	30.35	30.44	20.64	16.04
Crysvita Royalty	318.94	304	274.82	182.65	21.69	17.95
Revenue (Total)	717.21	673	560	434	363.33	351.41

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	436	737	745	777.11	896.73	999.13
Total Debt	1,202	1,252	910	934.74	907.03	393.76
Net Cash (Debt)	-766	-515	-165	-157.63	-10.3	605.37
Net Cash Growth	-	-	-	-	-	-26.90%
Net Cash Per Share	-7.62	-5.22	-1.82	-2.14	-0.15	8.93

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-485	-466	-414	-475	-380.47	-338.7
Capital Expenditures	-4	-6	-7	-44	-116.12	-73.09
Free Cash Flow	-489	-472	-421	-519	-496.59	-411.79
Free Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-20.78%	-27.64%	-38.39%	-59.68%	-102.05%	-46.03%
Operating Margin	-69.46%	-79.50%	-95.71%	-131.11%	-178.60%	-108.63%
Pretax Margin	-81.17%	-84.84%	-101.25%	-140.32%	-193.14%	-128.91%
Profit Margin	-81.73%	-85.44%	-101.61%	-139.86%	-194.70%	-129.20%
FCF Margin	-68.20%	-70.13%	-75.18%	-119.59%	-136.68%	-117.18%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 1, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	3.46	3.29	6.93	9.05	8.94	16.31